Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across ...

Plenty of folks have been using GLP-1s — generic versions of popular weight loss drugs such as Ozempic and Zepbound — to jump-start their health journeys lately. But those folks could be in for bad ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney ...

GLP-1 agonist semaglutide is the active ingredient in Novo Nordisk's blockbuster weight-loss drug Wegovy, which achieved sales of around $8 billion last year. Supply constraints have meant that ...

Weight loss drugs have surged in popularity. But Gov. Ned Lamont wants CT’s Medicaid program to discontinue covering them for ...